Study identifier:D5130L00053
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicentre, Open-label, Randomized, 6-week, Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared with Clopidogrel with Aspirin as Background Therapy in Chinese Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
Non-ST or ST Elevation Acute Coronary Syndromes
Phase 4
No
Ticagrelor, Clopidogrel
All
60
Interventional
18 Years - 150 Years
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Feb 2015 by AstraZeneca
AstraZeneca
-
The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.
Location
Location
Beijing, China
Location
Tianjin, China
Location
Shenyang, China
Arms | Assigned Interventions |
---|---|
Experimental: Ticagrelor | Drug: Ticagrelor 90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks. |
Active Comparator: clopidogrel | Drug: Clopidogrel 75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks. |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.